855 related articles for article (PubMed ID: 20027185)
1. Regulation of cell signalling by uPAR.
Smith HW; Marshall CJ
Nat Rev Mol Cell Biol; 2010 Jan; 11(1):23-36. PubMed ID: 20027185
[TBL] [Abstract][Full Text] [Related]
2. RhoB regulates uPAR signalling.
Alfano D; Ragno P; Stoppelli MP; Ridley AJ
J Cell Sci; 2012 May; 125(Pt 10):2369-80. PubMed ID: 22366462
[TBL] [Abstract][Full Text] [Related]
3. Role of urokinase receptor in tumor progression and development.
Noh H; Hong S; Huang S
Theranostics; 2013; 3(7):487-95. PubMed ID: 23843896
[TBL] [Abstract][Full Text] [Related]
4. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
Carriero MV; Stoppelli MP
Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
[TBL] [Abstract][Full Text] [Related]
5. The urokinase receptor as an entertainer of signal transduction.
D'Alessio S; Blasi F
Front Biosci (Landmark Ed); 2009 Jan; 14(12):4575-87. PubMed ID: 19273372
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
Czekay RP; Loskutoff DJ
J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
[TBL] [Abstract][Full Text] [Related]
7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
8. Regulation and role of urokinase plasminogen activator in vascular remodelling.
Tkachuk V; Stepanova V; Little PJ; Bobik A
Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
[TBL] [Abstract][Full Text] [Related]
9. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
10. The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins.
Ferraris GM; Schulte C; Buttiglione V; De Lorenzi V; Piontini A; Galluzzi M; Podestà A; Madsen CD; Sidenius N
EMBO J; 2014 Nov; 33(21):2458-72. PubMed ID: 25168639
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
[TBL] [Abstract][Full Text] [Related]
12. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling.
Blasi F; Sidenius N
FEBS Lett; 2010 May; 584(9):1923-30. PubMed ID: 20036661
[TBL] [Abstract][Full Text] [Related]
13. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
[TBL] [Abstract][Full Text] [Related]
14. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
15. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
[TBL] [Abstract][Full Text] [Related]
16. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Sidenius N; Blasi F
Cancer Metastasis Rev; 2003; 22(2-3):205-22. PubMed ID: 12784997
[TBL] [Abstract][Full Text] [Related]
17. Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.
Alfano D; Gorrasi A; Li Santi A; Ricci P; Montuori N; Selleri C; Ragno P
J Cell Mol Med; 2015 Sep; 19(9):2262-72. PubMed ID: 26082201
[TBL] [Abstract][Full Text] [Related]
18. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
19. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
20. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
